Join the Oncology Voice Network. Join for Free
Season 1, Episode 23: Revolutionizing Cancer Treatment with Paul Romness

Season 1, Episode 23: Revolutionizing Cancer Treatment with Paul Romness


Share This Article


Welcome back to the Pharmaverse, where we speak to the greatest voices in Pharma, to learn from their leadership and incredible careers! In this episode of the Pharmaverse podcast, host Michael Pietrack interviews Paul Romness, CEO of OS Therapies. The conversation delves into the inspiring story behind OS Therapies, which was founded in response to the osteosarcoma diagnosis of Olivia, a close friend of Paul’s daughter. We talk how to build incredible cultures! "The culture is set by the mission.” Paul discusses the innovative HER2 technology being developed to treat osteosarcoma and the importance of nonprofit partnerships in advancing research. He also shares insights into the ADC technology and its potential applications in cancer treatment. Throughout the discussion, Paul emphasizes the significance of leadership, company culture, and the personal sacrifices made in pursuit of a mission-driven approach to improving patient outcomes. Tune in to listen to the most incredible episode!

🟨 Takeaways

👧 OS Therapies was inspired by a personal story of a young girl named Olivia.

🧬 The HER2 technology aims to enhance overall survival rates in osteosarcoma patients.

📚 Nonprofit partnerships play a crucial role in funding and advancing research.

💉 ADC technology is a promising area in cancer treatment.

✅❌Leadership is shaped by experiences with both good and bad mentors.

🩺Company culture is driven by a mission focused on patient care.

🤝Hiring the right people is essential for maintaining a strong culture.

📱Networking is vital for finding passionate individuals to join the team.

💞Personal sacrifices are often necessary to pursue meaningful work.

🥅The ultimate goal is to improve treatment outcomes for pediatric cancer patients. 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN